Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Adams Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$7,688,673

266 payments

Through program year 2025, Adams Clinical Trials LLC is reported as receiving $7,688,673 in research payments, across 266 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $36,992 2
2023 Research $744,905 14
2022 Research $859,891 18
2021 Research $825,825 19
2020 Research $2,229,517 53
2019 Research $2,991,544 160

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $5,299,514 166 payments
  2. Allergan Inc. $1,313,211 71 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $989,375 5 payments
  4. Sunovion Pharmaceuticals Inc. $40,282 8 payments
  5. E.R. Squibb & Sons, L.L.C. $36,992 2 payments
  6. Indivior Inc. $9,300 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $2,763,555 105 payments
  2. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $2,304,457 46 payments
  3. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $754,249 23 payments
  4. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $732,898 1 payment
  5. A Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder $326,727 21 payments
  6. An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression $126,164 5 payments
  7. A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole $96,774 1 payment
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $81,936 2 payments
  9. Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $77,766 1 payment
  10. A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression $76,096 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record